Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00262-004-0557-1.

Title:
Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1) | Cancer Immunology, Immunotherapy
Description:
Purpose: CD227 (MUC1), a membrane-associated glycoprotein expressed by many types of ductal epithelia, including pancreas, breast, lung, and gastrointestinal tract, is overexpressed and aberrantly glycosylated by malignant cells. We sought to define epitopes on MUC1 recognized by the different cell-mediated immune responses by an in vivo assay. Epitopes identified by this assay were evaluated for efficacy to protect mice transgenic for human MUC1 (MUC1.Tg) against MUC1-expressing tumor growth. Methods: We investigated contributions of the tandem repeat (TR) and the cytoplasmic tail (CT) of MUC1 to the MUC1-specific immunological rejection of tumor cells. MUC1 cDNA constructs, in which the TR region was deleted or the CT was truncated, were transfected into two different murine tumor cell lines (B16 and Panc02), which were used to challenge mice and evaluate immunological rejection of the tumors. We used tumor rejection in vivo to define epitopes on the TR and CT of MUC1 recognized by T cell–mediated immune responses in a preclinical murine model. Results: Our findings demonstrated that the TR and a portion of the MUC1 CT contributed to CD4+ T cell rejection of MUC1-expressing B16 tumor cells, but not rejection of MUC1-expressing Panc02 tumor cells. A separate epitope in the CT of MUC1 was necessary for CD8+ T cell rejection of Panc02 tumor cells. Based on these studies, we sought to evaluate the efficacy of immunizing mice transgenic for (and immunologically tolerant to) human MUC1 with peptides derived from the amino acid sequence of the CT of MUC1. Results showed that survival can be significantly prolonged in vaccinated MUC1.Tg mice challenged with MUC1-expressing tumor cells, without induction of autoimmune responses. Conclusions: These studies demonstrated that MUC1 peptides may be utilized as an effective anticancer immunotherapeutic, and confirmed the importance of immunogenic epitopes outside of the TR.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,734,772 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

google, scholar, cas, pubmed, article, muc, cancer, tumor, mice, cells, immunol, immunity, hollingsworth, human, gendler, breast, transgenic, mucin, antigen, tempero, rejection, cell, int, immunother, biol, chem, vanlith, epitopes, responses, mucexpressing, access, epithelial, taylorpapadimitriou, privacy, cookies, content, immunotherapy, muctg, peptide, vaccines, kohlgraf, vivo, tandem, cdna, analysis, information, publish, research, search, cytoplasmic,

Topics {✒️}

tumour-draining lymph nodes muc1-specific anti-tumor responses month download article/chapter 0201-restricted t-cell epitopes cytotoxic t-lymphocyte responses sos/ras exchange protein anti-muc1 antibodies hmfg-2 muc1-expressing tumor cells muc1-expressing tumor growth hla-a11-restricted epitope vntr muc1-derived hla peptide-pulsed dendritic cells avidin-biotin-peroxidase complex human df3/muc1 carcinoma muc1-specific tumor immunity article cancer immunology cell-mediated immune responses cell–mediated immune responses tumor-selective monoclonal antibody monoclonal-antibody-defined antigens muc1-expressing pancreatic carcinoma muc1-specific immunological rejection individual peptide side-chains tumor cell type polymorphic epithelial mucin tumor-specific immunity panc02 tumor cells full article pdf epithelial mucin muc1 original article published inducing specific immunity muc1 tumor antigen privacy choices/manage cookies anti-muc1 class preclinical murine model related subjects di-leucine motif cd4-mediated responses barratt-boyes sm mouse mammary gland hla-a2/ protect mice transgenic muc1-transgenic mice muc1 transgenic mice immunodominant muc1 epitope human pancreatic tumors experimental vaccine strategies human breast carcinomas transgenic muc1 interacts immunizing mice transgenic

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1)
         description:Purpose: CD227 (MUC1), a membrane-associated glycoprotein expressed by many types of ductal epithelia, including pancreas, breast, lung, and gastrointestinal tract, is overexpressed and aberrantly glycosylated by malignant cells. We sought to define epitopes on MUC1 recognized by the different cell-mediated immune responses by an in vivo assay. Epitopes identified by this assay were evaluated for efficacy to protect mice transgenic for human MUC1 (MUC1.Tg) against MUC1-expressing tumor growth. Methods: We investigated contributions of the tandem repeat (TR) and the cytoplasmic tail (CT) of MUC1 to the MUC1-specific immunological rejection of tumor cells. MUC1 cDNA constructs, in which the TR region was deleted or the CT was truncated, were transfected into two different murine tumor cell lines (B16 and Panc02), which were used to challenge mice and evaluate immunological rejection of the tumors. We used tumor rejection in vivo to define epitopes on the TR and CT of MUC1 recognized by T cell–mediated immune responses in a preclinical murine model. Results: Our findings demonstrated that the TR and a portion of the MUC1 CT contributed to CD4+ T cell rejection of MUC1-expressing B16 tumor cells, but not rejection of MUC1-expressing Panc02 tumor cells. A separate epitope in the CT of MUC1 was necessary for CD8+ T cell rejection of Panc02 tumor cells. Based on these studies, we sought to evaluate the efficacy of immunizing mice transgenic for (and immunologically tolerant to) human MUC1 with peptides derived from the amino acid sequence of the CT of MUC1. Results showed that survival can be significantly prolonged in vaccinated MUC1.Tg mice challenged with MUC1-expressing tumor cells, without induction of autoimmune responses. Conclusions: These studies demonstrated that MUC1 peptides may be utilized as an effective anticancer immunotherapeutic, and confirmed the importance of immunogenic epitopes outside of the TR.
         datePublished:2004-06-25T00:00:00Z
         dateModified:2004-06-25T00:00:00Z
         pageStart:1068
         pageEnd:1084
         sameAs:https://doi.org/10.1007/s00262-004-0557-1
         keywords:
            Antitumor immunotherapy
            In vivo epitope mapping
            MUC1
            Tumor-associated antigens
            Tumor immunity
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1flb1.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1fhb2.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1fhb3.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1flb4.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1flb5.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1flb6.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1fhc7.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1flb8.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:53
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Karl G. Kohlgraf
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Andrew J. Gawron
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michiyo Higashi
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michelle L. VanLith
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:XiaoLing Shen
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thomas C. Caffrey
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Judy M. Anderson
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael A. Hollingsworth
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1)
      description:Purpose: CD227 (MUC1), a membrane-associated glycoprotein expressed by many types of ductal epithelia, including pancreas, breast, lung, and gastrointestinal tract, is overexpressed and aberrantly glycosylated by malignant cells. We sought to define epitopes on MUC1 recognized by the different cell-mediated immune responses by an in vivo assay. Epitopes identified by this assay were evaluated for efficacy to protect mice transgenic for human MUC1 (MUC1.Tg) against MUC1-expressing tumor growth. Methods: We investigated contributions of the tandem repeat (TR) and the cytoplasmic tail (CT) of MUC1 to the MUC1-specific immunological rejection of tumor cells. MUC1 cDNA constructs, in which the TR region was deleted or the CT was truncated, were transfected into two different murine tumor cell lines (B16 and Panc02), which were used to challenge mice and evaluate immunological rejection of the tumors. We used tumor rejection in vivo to define epitopes on the TR and CT of MUC1 recognized by T cell–mediated immune responses in a preclinical murine model. Results: Our findings demonstrated that the TR and a portion of the MUC1 CT contributed to CD4+ T cell rejection of MUC1-expressing B16 tumor cells, but not rejection of MUC1-expressing Panc02 tumor cells. A separate epitope in the CT of MUC1 was necessary for CD8+ T cell rejection of Panc02 tumor cells. Based on these studies, we sought to evaluate the efficacy of immunizing mice transgenic for (and immunologically tolerant to) human MUC1 with peptides derived from the amino acid sequence of the CT of MUC1. Results showed that survival can be significantly prolonged in vaccinated MUC1.Tg mice challenged with MUC1-expressing tumor cells, without induction of autoimmune responses. Conclusions: These studies demonstrated that MUC1 peptides may be utilized as an effective anticancer immunotherapeutic, and confirmed the importance of immunogenic epitopes outside of the TR.
      datePublished:2004-06-25T00:00:00Z
      dateModified:2004-06-25T00:00:00Z
      pageStart:1068
      pageEnd:1084
      sameAs:https://doi.org/10.1007/s00262-004-0557-1
      keywords:
         Antitumor immunotherapy
         In vivo epitope mapping
         MUC1
         Tumor-associated antigens
         Tumor immunity
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1flb1.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1fhb2.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1fhb3.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1flb4.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1flb5.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1flb6.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1fhc7.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-004-0557-1/MediaObjects/s00262-004-0557-1flb8.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:53
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Karl G. Kohlgraf
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Andrew J. Gawron
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michiyo Higashi
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michelle L. VanLith
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:XiaoLing Shen
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas C. Caffrey
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Judy M. Anderson
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael A. Hollingsworth
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:53
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Nebraska Medical Center
      address:
         name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Karl G. Kohlgraf
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:Andrew J. Gawron
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:Michiyo Higashi
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:Michelle L. VanLith
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:XiaoLing Shen
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:Thomas C. Caffrey
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:Judy M. Anderson
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:Michael A. Hollingsworth
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
      name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
      name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
      name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
      name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
      name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
      name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
      name:Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(135)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

4.31s.